Brief: Us FDA Awards Rare Pediatric Disease Designation To Paxalisib
06/07/2022 12:06
July 6 (Reuters) - Kazia Therapeutics Ltd KZA.AX :
* US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR
AT/RT,
A RARE FORM OF CHILDHOOD BRAIN CANCER
Source text for Eikon: ID:nPn48j0jja
Further company coverage: KZA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kazia Therapeutics
See all newsBrief: Kazia Therapeutics Files For Mixed Shelf Of Up To $100 Million – SEC Filing
Brief: Kazia Announces Voluntary Delisting From ASX
Australia's Kazia Therapeutics slumps to 1-yr low on delisting announcement
Brief: Kazia Therapeutics Announces Intention To Voluntarily De-List From ASX
Brief: Kazia Therapeutics Seeks Trading Halt